Melinta Therapeutics (CEMP) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access CEMP Annual Balance Sheets →
By examining balance sheet figures across successive periods, users can identify shifts in Melinta Therapeutics's financial structure and capital allocation.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2019)
(Jun 30 2019) (Mar 31 2019) (Dec 31 2018) (Sep 30 2018)
Assets
Cash & cash equivalent63.52
Cash & Short-term Investments63.00
Accounts receivable18.93
Other Receivables0.00
Inventories39.28
Prepaid Expense And Other Assets Current9.54
Total Current Assets131.27
Equipment/Property/Plant Net1.17
Goodwill net0.00
Intangible Assets40.10
Other Assets, Noncurrent55.96
Total Assets228.49
Liabilities
Accounts Payable, Current AC8.92
Accrued Liabilities, Current25.48
Other Liabilities, Current93.64
Total Current Liabilities128.05
Long-term debt89.08
Convertible Debt, Noncurrent LO63.72
Total Long-term Debt152.79
Other liabilities, Noncurrent8.18
Total Liabilities289.02
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock937.33
Retained Earnings / Accumulated Deficit-997.88
Other Equity0.00
Common Stockholder's Equity-60.53
Total Stockholder's Equity-60.53
Liabilities & Stockholder's Equity228.49
4 historic quarters locked

Sign in to unlock the full Melinta Therapeutics balance sheet history.

About CEMP Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.